Table 4. Progression-free and overall survival in MPC and LAPC cohorts.
|
Overall survival |
Progression-free survival |
|||||||
|---|---|---|---|---|---|---|---|---|
| Median OS | 6 mo | 12 mo | 18 mo | Median PFS | 6 mo | 12 mo | 18 mo | |
| Metastatic (37 pts) | 10.2 mo | 81% | 38% | 22% | 6.1 mo | 54% | 14% | 9% |
| LAPC (29 pts) | 26.6 mo | 100% | 86% | 62% | 17.8 mo | 97% | 69% | 62% |
Abbreviations: mo, months; Pts, patients.